IRAK4-IN-1

Cas No.:	1820787-94-7
Chemical Name:	Irak4-IN-1
Synonyms:	IRAK4-IN-1;4-[(4-morpholin-4-ylcyclohexyl)amino]quinazoline-6-carbonitrile;BCP32795;BDBM50242697
SMILES:	O1C([H])([H])C([H])([H])N(C([H])([H])C1([H])[H])C1([H])C([H])([H])C([H])([H])C([H])(C([H])([H])C1([H])[H])N([H])C1C2C([H])=C(C#N)C([H])=C([H])C=2N=C([H])N=1
Formula:	C19H23N5O
M.Wt:	337.4188
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.
Target:	IC50: 7 nM (IRAK4)[1]
In Vivo:	Oral pharmacokinetic studies of IRAK4-IN-1 (Compound 23) show it to have high bioavailability of 73% and low plasma clearance(Clp=22 mL/min/kg) leading to a reasonable half-life of 1.3 h[1].
In Vitro:	The in vitro metabolic stability profiles of IRAK4-IN-1 (Compound 23) is measured, with EC50 of 2300 nM for the rat whole blood (RWB) [1].
Animal Administration:	Rats[1] In the TLR driven in vivo model, female Lewis rats are dosed with either vehicle or IRAK4-IN-1 (Compound 23; 3, 10, 30, and 100 mg/kg; p.o.) dosed at 1 h prior to stimulation with Resiquimod, R848 (5 mg/kg, IP). At 1.5 h post R848 stimulation, blood samples are obtained from the animals and cytokine levels are measured.
References:	[1]. Smith GF, et al. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2721-2726.